Bartolini P, De Assis L M, Fonseca M L
Clin Chim Acta. 1981 Mar 5;110(2-3):177-85. doi: 10.1016/0009-8981(81)90347-8.
The radioiodination and chromatographic purification of human growth hormone (hGH) has been studied in order to better define and control the so-called "preparation damage", which is often a cause of interferences, loss in specific activity and sensitivity, misclassification errors in radioligand assays, and a source of misinterpretation when the tracer is used in receptors or in vivo studies. A series of labelings and false labelings, with and without protein carrier in the buffer used for Sephadex purification, indicate that the "preparation damage" peak is made up of two components: aggregated 125I-hGH and BSA-carried radioactivity. The former can be minimized by the use of recently extracted non-lyophilized hGH, and the latter by enzymatic labeling. Both components can be better resolved, and thus eliminated, when Sephadex G-100 is employed rather than G-75.
为了更好地界定和控制所谓的“制剂损伤”，对人生长激素（hGH）的放射性碘化和色谱纯化进行了研究。“制剂损伤”常常是干扰的原因、比活性和灵敏度的损失、放射配体分析中的错误分类误差，以及当示踪剂用于受体或体内研究时产生错误解释的根源。在用于葡聚糖凝胶纯化的缓冲液中，进行了一系列有无蛋白质载体的标记和错误标记，结果表明，“制剂损伤”峰由两种成分组成：聚集的¹²⁵I-hGH和牛血清白蛋白携带的放射性。前者可通过使用最近提取的非冻干hGH来最小化，后者可通过酶促标记来最小化。当使用葡聚糖凝胶G-100而不是G-75时，两种成分可以得到更好的分离，从而消除。
